Cryosite Limited (AU:CTE)
ASX:CTE
Want to see AU:CTE full AI Analyst Report?
CTE Stock Chart & Stats
AU$1.00
-AU$0.05(-6.02%)
At close: 4:00 PM EST
AU$1.00
-AU$0.05(-6.02%)
Day’s Range― - ―
52-Week RangeAU$0.60 - AU$1.30
Previous CloseN/A
Volume1.46K
Average Volume (3M)1.97K
Market Cap
AU$51.74M
Enterprise ValueAU$59.97M
Total Cash (Recent Filing)AU$2.54M
Total Debt (Recent Filing)AU$8.82M
Price to Earnings (P/E)23.7
Beta-0.20
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio8.08
Price to Book (P/B)15.22
Price to Sales (P/S)2.58
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High MarginsSustained high gross (62.98%) and solid net margins indicate durable product pricing power and operational efficiency. Such margin levels support reinvestment in R&D, buffer against cost inflation, and underpin long-term profitability even if revenue growth moderates.
Consistent Revenue GrowthRecurring mid-single-digit revenue growth demonstrates steady demand and market traction in diagnostics. Reliable top-line expansion enables scale benefits, supports fixed-cost absorption and provides a foundation for sustainable margin maintenance and investment over the next several quarters.
High ROEA very high ROE reflects efficient use of shareholder capital to generate profits, signaling strong operating returns and management effectiveness. If maintained, this supports continued capital allocation to growth initiatives and creates long-term shareholder value.
Bears Say
Free Cash Flow DeclineA sharp 32.88% drop in free cash flow growth is a structural concern: it reduces financial flexibility for capex, acquisitions, or dividends. Persisting FCF decline can force reliance on external funding and constrain long-term strategic investments.
Weak Cash ConversionOCF failing to cover net income signals earnings may include non-cash items or working capital drags. Poor cash conversion undermines earnings quality and can strain liquidity under slower sales, limiting the company's ability to self-fund growth or service obligations reliably.
Leverage RelianceLeverage near 1.0 and a low equity base increase financial risk, raising interest burden and reducing shock absorbency. In a downturn or with tighter credit, this reliance on debt could restrict strategic options and elevate refinancing or covenant risks over the medium term.
Cryosite Limited News
CTE FAQ
What was Cryosite Limited’s price range in the past 12 months?
Cryosite Limited lowest share price was AU$0.60 and its highest was AU$1.30 in the past 12 months.
What is Cryosite Limited’s market cap?
Cryosite Limited’s market cap is AU$51.74M.
When is Cryosite Limited’s upcoming earnings report date?
Cryosite Limited’s upcoming earnings report date is Aug 21, 2026 which is in 76 days.
How were Cryosite Limited’s earnings last quarter?
Cryosite Limited released its earnings results on Feb 26, 2026. The company reported AU$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.023.
Is Cryosite Limited overvalued?
According to Wall Street analysts Cryosite Limited’s price is currently Overvalued.
Does Cryosite Limited pay dividends?
Cryosite Limited pays a Annually dividend of AU$0.02 which represents an annual dividend yield of N/A. See more information on Cryosite Limited dividends here
What is Cryosite Limited’s EPS estimate?
Cryosite Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cryosite Limited have?
Cryosite Limited has 48,809,563 shares outstanding.
What happened to Cryosite Limited’s price movement after its last earnings report?
Cryosite Limited reported an EPS of AU$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cryosite Limited?
Currently, no hedge funds are holding shares in AU:CTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryosite Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
72.82%
Trailing 12-Months
Asset Growth
39.09%
Trailing 12-Months
Company Description
Cryosite Limited
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---